IONS ▲ +3.6% - Ionis Pharmaceuticals, Inc. $IONS Ionis / Roche: Sefaxersen Hits Phase 3 Primary Endpoint in IgA Nephropathy ? • Interim Phase 3 showed statistically significant, clinically meaningful proteinuria reduction at Week 37. • Safety was consistent with prior studies, with no new signals; trial continues through Week 105. • Ionis remains eligible for regulatory and sales milestones plus tiered royalties on net sales. Ionis shares rose 3.6% after the company announced that sefaxersen, developed with Roche, met its primary endpoint in a Phase 3 trial for IgA nephropathy, demonstrating statistically significant and clinically meaningful reduction in proteinuria at Week 37 while maintaining a consistent safety profile. The achievement keeps Ionis eligible for regulatory and sales milestones plus tiered royalties, validating the therapeutic approach and de-risking the program's path toward potential commercialization. 23-SEP-2026 05:27 AM ET